An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

ClinicalTrials.gov ID

NCT06693336

Lead Sponsor

ToLymph Inc.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

42Estimated

Last Update Posted

Mar 6, 2026Actual

Start Date

Nov 18, 2024Actual

Primary Completion Date

Nov 18, 2026Estimated

Completion Date

Dec 30, 2026Estimated

Official Title

Phase IIa Trial Evaluating the Safety and Therapeutic Effect of SMS001 as an Adjuvant Therapy to Control Tumor Recurrence in Stage Ib-IIIa (N2) Non-Small Cell Lung Cancer (NSCLC) Patients

Brief Summary

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Detailed Description

PRIMARY OBJECTIVES:

1. To evaluate the safety and tolerability of SMS001 in Non-Small Cell Lung Cancer (NSCLC) patients undergoing cancer surgery.

SECONDARY OBJECTIVES:

1. To evaluate tumor recurrence at 12-month follow-up in NSCLC lung cancer patients treated at a predefined dose.
2. To evaluate disease free survival (DFS) for patients treated with SMS001 at the end of study.

• Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

• SMS001

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Histopathological confirmed NSCLC

2. Stage Ib, IIa, IIb or IIIa (N2) for both dose escalation and dose confirmation (NOTE: Staging will be according to the AJCC 8th edition)

3. Age ≥18 years and suitable for lung cancer surgery

4. No prior chemotherapy and/or thoracic radiation therapy

5. Normal liver, and renal function at study entry

6. Laboratory requirements:

   1. WBC > 2500/mm3
   2. Neutrophil >1500/mm3
   3. Hemoglobin >10 g/dL
   4. Platelet >100,000/ mm3
   5. AST and ALT < 2.5 x ULN
   6. Total bilirubin < 1.5 x ULN
   7. Creatinine < 2 mg/dL (equivalent to 176.8 μmol/L)
   8. Normal PT/INR and PTT
   9. eGFR >60mL/min/1.73m²

7. QT interval corrected for heart rate using Frederica's formula (QTcF): males < 450msec and females < 470msec

8. Operating surgeon deems patient is candidate for complete surgical resection of lung cancer and lymphadenectomy or lymph node sampling (Wedge resection, segmentectomy or lobectomy are acceptable)

9. Stated willingness to comply with all study procedures and availability for the duration of the study

10. Ability to understand and sign informed consent

11. Women of childbearing potential (WOCBP) must use highly effective methods of contraception for at least 6 months after wafer insertion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥40 mIU/mL [or ≥ 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile. Men must use highly effective methods of contraception for at least 3 months after wafer insertion. Examples of highly effective contraception include: parenteral contraceptives, oral contraceptives, patch contraceptives, implantable hormonal contraceptives, intrauterine device or system, surgical sterilization (hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy), tubal ligation/occlusion, vasectomized partner, or sexual abstinence, if this is the subject's current practice. Periodic abstinence, i.e., calendar, symptothermal, or post-ovulation methods are not an acceptable form of contraception for this study.

Exclusion Criteria:

If a subject meets any of the following criteria, he/she must be excluded from the study.

1. Evidence of locally advanced T3 or T4 NSCLC or distant metastatic disease.
2. Patients requiring pneumonectomy or sleeve resection.
3. Known sensitivity to any of the study agent components.
4. Patients with a previous malignancy within the last 5 years except non-melanoma skin cancer.
5. Patients receiving induction (neo-adjuvant) chemotherapy and/or radiation prior to surgery.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. dysfunction of major organ (e.g., liver, kidney etc.), symptomatic congestive heart failure. unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
7. Pregnant or nursing female subjects.
8. Unwilling or unable to follow protocol requirements.
9. Any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

ToLymph Inc.INDUSTRY

Collaborators

University Health Network, TorontoOTHER

Mayo Clinic, Rochester, MNUNKNOWN

• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

  NCT01024062

  CompletedInterventionalPhase 2Updated Apr 25, 2011
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

  NCT00850577

  TerminatedInterventionalPhase 2Updated Oct 12, 2015
• A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

  NCT00386555

  WithdrawnInterventionalPhase 2Updated Aug 9, 2012
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

  NCT00527735

  CompletedInterventionalPhase 2Updated Jul 18, 2018
• Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

  NCT00061646

  TerminatedInterventionalPhase 2Updated Aug 14, 2007
• S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

  NCT00002969

  CompletedInterventionalPhase 2Updated Jul 24, 2012

kazuhiro.yasufuku@uhn.ca416-340-4798